Scarica l'app Stockscreener
48.72
0.61%
-0.30
Dopo l'orario di chiusura:
48.81
0.09
+0.18%
Spruce Biosciences Inc Borsa (SPRB) Ultime notizie
SPRB Reiterated by Citizens -- Price Target Maintained at $144 - GuruFocus
Citizens reiterates Spruce Biosciences stock rating on therapy lead - Investing.com
Spruce Biosciences, Inc.(NasdaqCM: SPRB) added to S&P Global BMI Index - marketscreener.com
Spruce Biosciences Stock Price Forecast. Should You Buy SPRB? - StockInvest.us
Lake Street Initiates Spruce Biosciences at Buy With $149 Price Target - Yahoo Finance
Citizens reiterates Spruce Biosciences stock rating on gene therapy approval - Investing.com
Citizens reiterates Spruce Biosciences stock rating on gene therapy approval By Investing.com - Investing.com Canada
SPRB Initiated Coverage by Lake Street -- Price Target Announced at $149 - GuruFocus
Spruce Biosciences Initiated at Buy by Lake Street - Moomoo
Lake Street Initiates Spruce Biosciences(SPRB.US) With Buy Rating, Announces Target Price $149 - Moomoo
Spruce Biosciences at H.C. Wainwright: BLA path comes into focus By Investing.com - Investing.com Canada
Spruce Biosciences, Inc. (SPRB) Stock Price, News, Quote & History - Yahoo! Finance Canada
Guggenheim initiates coverage on Spruce Biosciences with Buy rating - scanx.trade
Spruce Biosciences to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - BioSpace
Spruce Biosciences, Inc. Common Stock (NASDAQ: SPRB) Stock Price, News & Analysis - kalkine.ca
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Why is Spruce Biosciences stock gaining 4% today? By Investing.com - Investing.com Canada
Spruce Biosciences stock gains after analyst backs regulatory progress - Yahoo Finance
Spruce Biosciences Announces Launch of MPS3BStudy.com - Yahoo Finance
H.C. Wainwright reiterates Spruce Biosciences stock rating on BLA progress By Investing.com - Investing.com UK
Oppenheimer Maintains Spruce Biosciences(SPRB.US) With Buy Rating, Maintains Target Price $230 - Moomoo
Spruce’s successful FDA talks plant seeds for Q4 filing of ultra-rare disease drug - fiercebiotech.com
Spruce (SPRB) Q2 2026 Earnings: The Bottom-Line Figure Trails Its Comparison in the Latest Session; Reaction Snapshot: Shares Finish 0.14% Lower in the Current UpdateNon-GAAP Earnings - vinanet.vn
Spruce Biosciences receives $5.5M from patient advocacy groups By Investing.com - Investing.com Nigeria
Guggenheim lowers Spruce Biosciences stock price target to $104 By Investing.com - Investing.com South Africa
SPRB Maintained by Guggenheim -- Price Target Lowered to $104 - GuruFocus
Guggenheim lowers Spruce Biosciences stock price target to $104 - Investing.com
Spruce Biosciences (SPRB) Climbs 5.77% to $52.64 as Momentum Builds Toward $55.27 ResistanceBPI Reversal - vinanet.vn
Spruce Biosciences (NASDAQ:SPRB) Downgraded to Strong Sell Rating by Wall Street Zen - MarketBeat
OrbiMed discloses 7.3% ownership of Spruce Biosciences (SPRB) common stock - Stock Titan
Spruce Biosciences | SCHEDULE 13G: Others - Moomoo
Spruce Biosciences | SCHEDULE 13G/A: Others - Moomoo
Spruce Biosciences (SPRB): ADAR1, Schneeberger disclose 2.5% beneficial stake - Stock Titan
Citadel entities and Kenneth Griffin (SPRB) report 1.9% beneficial stake in Spruce - Stock Titan
Spruce Biosciences (SPRB) sees AWM Investment disclose 5.1% equity stake - Stock Titan
SPRB Maintained by Citizens -- Price Target Lowered to $144 - GuruFocus
Craig-Hallum Maintains Spruce Biosciences(SPRB.US) With Buy Rating, Maintains Target Price $140 - Moomoo
Spruce Biosciences (NASDAQ:SPRB) Given New $144.00 Price Target at Citizens Jmp - MarketBeat
Spruce Biosciences (SPRB) Rises 1.42% as Shares Approach Key Resistance at $49.42Extension Target - vinanet.vn
Citizens cuts Spruce Biosciences stock price target on share dilution By Investing.com - Investing.com Australia
Citizens cuts Spruce Biosciences stock price target on share dilution - Investing.com
Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates - biospace.com
Spruce Biosciences (NASDAQ:SPRB) Issues Quarterly Earnings Results, Misses Estimates By $0.89 EPS - MarketBeat
Spruce Biosciences Q2 Results: EPS Misses Estimate, Losses Widen 91% YoY - scanx.trade
Spruce Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Form 8K Spruce Biosciences Inc For: 12 August By Investing.com - Investing.com South Africa
Spruce Biosciences, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
SPRUCE BIOSCIENCES, INC. 2Q 2026: Net loss $(16.2M), EPS $(6.68) — 10-Q Summary - TradingView
SPRB: TA-ERT BLA submission and confirmatory study set for Q4 2026, with strong cash reserves and new leadership - TradingView
Spruce Biosciences reports Q2 2026 net loss $16.2M, cash $96.3M; BLA for TA-ERT expected Q4 2026 - TradingView
Spruce Biosciences Q2 2026 Results: Expenses Rise Ahead of the TA-ERT Filing - TradingKey
SPRB: Q2 2026 net loss rose to $16.2M as R&D spending surged, with $96.3M in cash on hand - TradingView
Spruce Biosciences (SPRB) ramps TA-ERT spend while lifting cash to $96.3M - Stock Titan
Spruce Biosciences posts $16.2 million Q2 net loss - Quiver Quantitative
Spruce Biosciences Q2 net loss widens on higher expenses - TradingView
8-K: Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updatesmoomoo - Moomoo
3.06%
2.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):